EIN 20-3347314

Global HIV Vaccine Enterprise

IRS 501(c) type
501(c)(3)
Num. employees
7
Year formed
2005
Most recent tax filings
2017-12-01
Notice
This nonprofit is terminated or no longer active
Global HIV Vaccine Enterprise may be no longer active or terminated. Either the organization hasn't filed a Form 990 in many years and appears to no longer be active, or they marked in their most recent Form 990 that they have closed down.
Description
The Global HIV Vaccine Enterprise (the Enterprise) is an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine.
Total revenues
$1,160,530
2017
Total expenses
$3,698,291
2017
Total assets
$2,976,032
2017
Num. employees
7
2017

Program areas at Global HIV Vaccine Enterprise

Meetings/program - a) strategic convening/timely topics in Hiv vaccines series: the search for a safe and effective Hiv Vaccine has progressed further and faster in the last few years than at any time since the epidemic began. This progress poses new questions, new opportunities and new challenges as to what and how the Hiv Vaccine research endeavor should move forward. To help identify and respond to unresolved and emerging priority issues and move Hiv Vaccine r&d forward, the Enterprise produces its timely topics in Hiv vaccines series. Through an open call for proposals, the Enterprise identifies the most strategic needs of the field and sponsors think tanks, meetings, forums and other events in addition to developing useful tools to tackle these issues. Issues addressed to date include vaccine-induced sero-positivity/ sero-reactivity, a mucosal guide, and antibody durability, among others. B) to strengthen recognition of the Enterprise mission, programs, stakeholder goals and achievements, as well as keep current on the state of Hiv Vaccine research, the Enterprise secretariat participated in various scientific and advisory meetings and discussions with partners and stakeholders. Through these interactions, the Enterprise helped to connect partners, coordinate efforts, share information, and support stakeholders in coordinated Vaccine research and development efforts.
Conference - Hiv research for prevention (r4p) conference: the Global Hiv Vaccine Enterprise (Enterprise) began preparations for the hivr4p conference to be held from october 21st to 25th, 2018 in madrid, spain. This biennial conference is the leading Global forum for scientific exchange on Hiv Vaccine research and helps to increase coordination in our collective effort to develop an Hiv Vaccine. The conference will be attended by more than 1400 researchers, funders, advocates, and policymakers, feature daily plenary presentations by leading researchers and clinicians along with symposia and oral abstract and poster sessions addressing every aspect of Vaccine development and testing. Hivr4p 2018 will host many opportunities for young and early career investigators to share ideas and approaches and network with peers and senior researchers.

Who funds Global HIV Vaccine Enterprise

Federal funding details
Federal agencyProgram nameAmount
Department of Health and Human ServicesALLERGY IMMUNOLOGY AND TRANSPLANTATION RESEARCH$1,237,249
National Science FoundationOFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING$711,338

Financials for Global HIV Vaccine Enterprise

RevenuesFYE 12/2017
Total grants, contributions, etc.$1,160,530
Program services$0
Investment income and dividends$0
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$0
Net gain from sale of non-inventory assets$0
Net income from fundraising events$0
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$0
Total revenues$1,160,530

Form 990s for Global HIV Vaccine Enterprise

Fiscal year endingDate received by IRSFormPDF link
2017-122018-12-22990View PDF
2016-122017-12-18990View PDF
2015-122016-10-24990View PDF
2014-122015-11-25990View PDF
2013-122014-09-23990View PDF
...and 3 more Form 990s
Data update history
October 28, 2020
Updated personnel
Identified 1 new personnel
March 5, 2020
Used new vendors
Identified 1 new vendor, including
July 24, 2019
Updated personnel
Identified 10 new personnel
December 30, 2018
Used new vendors
Identified 2 new vendors, including , and
November 26, 2018
Posted financials
Added Form 990 for fiscal year 2017
Nonprofit Types
Social advocacy organizationsResearch centers
Issues
Social sciencesDiseases and disorders
Characteristics
Conducts researchOperates internationallyNational levelReceives government fundingTerminated
General information
Address
64 Beaver St Suite 352
New York, NY 10004
Metro area
New York-Newark-Jersey City, NY-NJ-PA
County
New York County, NY
Website URL
iasociety.org/ias-programme/global-hiv-vaccine-enterprise 
Phone
(212) 461-3692
Facebook page
hiventerprise 
IRS details
EIN
20-3347314
Fiscal year end
December
Taxreturn type
Form 990
Year formed
2005
Eligible to receive tax-deductible contributions (Pub 78)
No
Categorization
NTEE code, primary
V00: Social Science Research: General
NAICS code, primary
813319: Social Advocacy Organizations
Parent/child status
Independent
Free account sign-up

Want updates when Global HIV Vaccine Enterprise has new information, or want to find more organizations like Global HIV Vaccine Enterprise?

Create free Cause IQ account